Table 1

Main characteristics of 16 patients with primary Sjögren’s syndrome, treated with rituximab (first treatment)

Patient	Sex/age/disease duration (years)	pSS status: anti-SSA/SSB antibodies/Chisolm–Mason score	Prior Immunosuppressive treatments	Clinical involvement at the beginning of RTX	Number of infusions × dose	Associated immunosuppressor treatments	Adverse event (Y/N)	Efficacy for lymphoma	Efficacy for systemic features	Efficacy for dryness ocular/oral (Y/N)		Follow-up(months)	Prednisone (mg/day) first/last	RF (IU/l)first/last	γ-globulinaemia (g/l) first/last
Patient	Sex/age/disease duration (years)	pSS status: anti-SSA/SSB antibodies/Chisolm–Mason score	Prior Immunosuppressive treatments	Clinical involvement at the beginning of RTX	Number of infusions × dose	Associated immunosuppressor treatments	Adverse event (Y/N)	Efficacy for lymphoma	Efficacy for systemic features	Subjective	Objective	Follow-up(months)	Prednisone (mg/day) first/last	RF (IU/l)first/last	γ-globulinaemia (g/l) first/last
AZA, azathioprine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CPH, cyclophosphamide; d-peni, d penicillamine; ETA, etanercept; F, female; HQ, hydroxy-chloroquine; IFLX, infliximab; IRR, infusion-related reaction; iv, intravenous; Leflu, leflunomide; MALT, mucosa-associated lymphoid tissue; MMF, mycophenolate mofetil; MTX, methotrexate; N, no; NA, not available; NR, not relevant; pSS, primary Sjögren’s syndrome; RF, rheumatoid factor; RTX, rituximab; SSA, Sjögren’s syndrome antigen; SSB, Sjögren’s syndrome B; SSR, serum sickness-like reaction; SZP, salazopyrine; Y, yes.
*Four patients had already been reported in a previous study.¹¹
1	F/59/25	SSA SSB/IV	No	Polysynovitis and glandular swelling (cutaneous nodules)	4×375 ms	No	Y(IRR)	NR	Y	N/N	N/N	15	30/0	1040/415	35.4/26.7
											Persitant keratitis
											Salivary flow = 0
2	F/44/10	SSA SSB/IV	HQ/MTX/	Pulmonary, renal	4×375 ms	No	N	NR	Y	N/N	N/N	17	30/10	1250/499	87/38
			Leflu/IFLX/	involvements and							Stable Schirmer
			ETA/MMF	polysynovitis							Salivary flow = 0
3*	F/43/4	SSA SSB/NA	No	Salivary lymphoma (MALT)	4×375 ms	No	Y(SSR)	N	NR	N/N	NA/NA	14	0/0	499/423	31/26
4	F/71/10	0/III	MTX	Nodal marginal zone lymphoma	4×375 ms	No	Y(IRR)	Y	NR	Y/N	Y/N	13	0/0	31.5/0	15.8/13.6
											Regression of keratitis
											Stable salivary flow
5*	F/71/5	SSA/IV	CPH/HQ/	Cryoglobulinaemia	4×375 ms	No	N	NR	Y	N/N	N/N	27	30/7.5	109/113	8.8/4.6
			AZA								Stable Schirmer
											Salivary flow = 0
6	F/53/13	SSA SSB/IV	CPH/AZA	Cryoglobulinaemia	4×375 ms	No	N	NR	Y	N/N	N/N	21	15/0	55/5	9.2/7
											Stable Schirmer
											Salivary flow = 0
7	F/67/18	SSA/NA	CPH	Gastric, pulmonary lymphoma (MALT)	6×375 ms	Mini-CHOP	N	Y	NR	N/N	NA/NA	48	7.5/7.5	270/0	8.6/7.5
8*	F/58/15	SSA/IV	HQ	Gastric lymphoma (MALT)	4×375 ms	HQ	N	Y	NR	Y/N	Y/NA	24	17.5/5	44/0	10.7/6.5
											Regression of keratitis
9	F/54/4	SSA SSB/IV	CPH/MMF	Mononeuritis multiplex	4×375 ms	No	N	NR	Y	Y/Y	N/NA	13	8/7	139/22	13.4/9.6
											Stable Schirmer
10	F/69/12	No/III	HQ/MTX/Leflu/D-peni/IL1RA	Polysynovitis	4×375ms	Leflu	N	NR	Y	N/N	N/NA	12	10/7.5	0/0	24.9/14
											Stable Schirmer
11	F/63/6	SSA SSB/IV	SZP/goldsalts	Immune mediated thrombocytopenia	4×375 ms	No	N	NR	N	N/N	N/N	8	5/5	44/22	37.5/26
											Stable Schirmer
											Salivary flow = 0
12*	F/58/2	SSA/NA	CPH	Cryoglobulinaemia	4×375 ms	No	N	NR	Y	NA/NA	NA/NA	25	10/0	170/0	4.8/4.6
13	F/41/9	No/IV	CHP/AZA/	Diffuse large B cell lymphoma	4×375 ms	CHOP	N	Y	NR	Y/N	N/N	15	10/0	NA/0	2.3/4.0
			MTX/HCQ								Stable Schirmer
											Salivary flow = 0
14	F/66/20	No/IV	CPH/AZA/	Cryoglobulinaemia	4×375 ms	No	N	NR	Y	N/N	N/N	12	30/10	NA/NA	4.5/5.3
			MTX								Worsened Schirmer
											Salivary flow = 0
15	F/66/0	SSA/IV	No	Cryoglobulinaemia	4×375 ms	No	N	NR	N	Y/NA	NA/NA	14	0/0	512/NA	NA/NA
16	F/57/3	SSA/II	HQ/MTX	Polysynovitis and pulmonary involvement	2×1 g	No	N	NR	Y	NA/NA	NA/NA	2	30/5	0/0	16.7/15.2